French speciality biotech company Valneva has initiated a phase I/II clinical trial of its inactivated and adjuvanted COVID-19 vaccine, VLA2001, in the UK. The study will be conducted in four study sites across the UK and will also be supported by the National Institute for Health Research (NIHR). Source: Pharmatimes  17/12/2020